Wegovy Linked to 5x Higher Vision Loss Risk (Study)

Affiliate Disclosure: The GLP-1 Daily may earn a commission from products recommended in this article. This does not influence our editorial coverage or recommendations.

---

Quick Answer

• A March 2026 study in the British Journal of Ophthalmology found Wegovy users have roughly 5 times the odds of developing "eye stroke" (NAION) compared to Ozempic users, likely due to the higher 2.4 mg dose.
• NAION is rare — affecting roughly 1 in 10,000 semaglutide users — but causes sudden, painless, and often permanent vision loss in one eye.
• Men appear to face 3 times the NAION risk of women, and injectable formulations carry more risk than the oral tablet Rybelsus, which showed no detectable link.
• Experts stress this is not a reason to stop medication without consulting a doctor — the absolute risk remains very low, and the cardiovascular and metabolic benefits of GLP-1 drugs are well established.

---

What the New Study Found

A team led by researchers M. Lakhani, Al-Ani, Popovic, Bénard-Séguin, and Dr. Edward Margolin from the University of Toronto published a study in the British Journal of Ophthalmology in March 2026 that has reignited concerns about a link between semaglutide and a rare but serious eye condition called non-arteritic anterior ischemic optic neuropathy, or NAION.

NAION is sometimes called an "eye stroke." It occurs when blood flow to the optic nerve — the cable that carries visual signals from the eye to the brain — is suddenly and severely restricted. The result is typically sudden, painless vision loss in one eye. Unlike many other eye conditions, NAION damage is generally irreversible, and there is currently no effective treatment once it occurs.

The researchers analyzed adverse event reports submitted to the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) between December 2017 and December 2024 — a database containing more than 30 million reports. Their goal was to compare rates of ischemic optic neuropathy (ION) across different semaglutide formulations and doses.

The Key Numbers

The findings were striking:

• Wegovy (semaglutide 2.4 mg injection): Approximately 5 times higher odds of ION compared to Ozempic
• Ozempic (semaglutide up to 2.0 mg injection): Baseline comparison — lower risk than Wegovy despite roughly 21,000 incident reports in the database vs. about 3,000 for Wegovy
• Rybelsus (oral semaglutide tablet): No detectable increased risk of NAION
• Mounjaro (tirzepatide): No increased risk detected in this analysis
• Sex-based difference: Men faced approximately 3 times higher odds of NAION than women
• Overall incidence: Roughly 1 in 10,000 semaglutide users (very rare by clinical standards)

The fact that Wegovy had far fewer total adverse event reports than Ozempic yet was "most strongly correlated with ION" made the signal particularly noteworthy to the research team.

Why Wegovy May Carry Higher Risk Than Ozempic

The study's most important contribution may be the dose-dependent pattern it reveals. Wegovy is prescribed at up to 2.4 mg per week for weight management, while Ozempic tops out at 2.0 mg per week for type 2 diabetes. That 20% dosage difference appears to matter.

Dr. Edward Margolin, a neuro-ophthalmologist at the University of Toronto and senior author on the study, proposed that "faster, quicker, or more aggressive weight loss would be likely to increase the risk of NAION." The hypothesis is that the physiological stress of rapid weight loss — including shifts in blood pressure, fluid balance, and vascular tone — may compromise blood flow to the optic nerve in susceptible individuals.

The oral tablet form, Rybelsus, showed no detectable link to NAION. Researchers attributed this to the "limited absorption and slower uptake" of the oral formulation, which produces lower peak drug concentrations in the bloodstream compared to injections.

This pattern suggests the risk is not simply about semaglutide as a molecule, but about how much of it reaches the body, how quickly, and how aggressively it drives weight loss. If you are weighing your options between different GLP-1 medications, our [semaglutide vs. tirzepatide comparison](/semaglutide-vs-tirzepatide) covers the broader efficacy and safety differences.

This Is Not the First Warning Sign

The March 2026 study builds on a growing body of evidence that has been accumulating since mid-2024.

The Mass General Brigham Study (July 2024)

The first major alarm came from Dr. Joseph Rizzo at Mass Eye and Ear, part of the Mass General Brigham health system. His team analyzed records of 17,000 patients since Ozempic received FDA approval and evaluated more than 600 NAION cases diagnosed over six years. The findings, published in JAMA Ophthalmology:

• Diabetes patients on semaglutide: 4 times more likely to develop NAION than those not on the drug (hazard ratio 4.28)
• Overweight/obese patients on semaglutide (without diabetes): 7 times more likely to develop NAION (hazard ratio 7.64)

The higher risk in weight-loss patients compared to diabetes patients was a particularly concerning finding, because millions of people without diabetes now use semaglutide purely for weight management.

Systematic Review and Meta-Analysis (2025)

A systematic review and meta-analysis published in the scientific literature pooled data from multiple studies and found a statistically significant increased risk of NAION with semaglutide use, with a pooled hazard ratio of 2.62 (95% confidence interval: 1.81-3.80, P < 0.001). The analysis also showed that the risk became statistically significant after approximately 2 years of exposure, suggesting a cumulative or time-dependent component.

Large Multicenter Study (37 Million Patients)

A separate large study reviewing approximately 37 million adult records with type 2 diabetes across 14 databases confirmed a "small increase in the relative incidence of NAION from semaglutide exposure," though the effect size was smaller than Dr. Rizzo's earlier findings. This study provided reassurance that the absolute risk remains low even if the relative risk is elevated.

WHO and EMA Action (2025)

In June 2025, the World Health Organization's Advisory Committee on Safety of Medicinal Products evaluated the evidence and recommended that the Risk Management Plan for semaglutide be revised to include NAION as a potential risk. The European Medicines Agency (EMA) followed by recommending that product information for Ozempic, Wegovy, and Rybelsus be updated to list NAION as a side effect, classified as "very rare."

FDA Sends Warning Letter to Novo Nordisk

Adding to the scrutiny, the FDA sent a warning letter to Novo Nordisk in early March 2026, accusing the company of failing to develop proper procedures for reporting side effects related to its GLP-1 drugs. According to reporting from Drugwatch, the FDA alleged that Novo Nordisk had failed to report the deaths of three patients taking GLP-1 medications, including one case involving a patient suicide.

The FDA did not say that the drugs were responsible for these deaths. However, the letter underscores growing regulatory frustration with adverse event reporting gaps for a drug class that is now used by tens of millions of people worldwide. Novo Nordisk was given 15 business days to respond with an explanation of corrective actions.

This regulatory pressure is separate from the NAION research, but the timing highlights the broader need for more transparent safety monitoring of GLP-1 drugs as their use continues to expand beyond the diabetes population into general weight management.

Understanding the Risk: Absolute vs. Relative

Headlines that say "5 times higher risk" are alarming. But context matters enormously when interpreting medical statistics, and the distinction between relative risk and absolute risk is critical here.

Relative Risk

The study found that Wegovy users have roughly 5 times the odds of developing ION compared to Ozempic users. That is a large relative increase. But "5 times a very small number" is still a small number.

Absolute Risk

NAION affects approximately 1 in 10,000 semaglutide users overall. Even if Wegovy's specific rate were 5 times higher than Ozempic's rate, the absolute probability for any individual Wegovy user remains very low — likely in the range of a few cases per 10,000 users.

For comparison, the cardiovascular benefits of semaglutide are well established. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in overweight or obese adults without diabetes. For many patients, particularly those with elevated cardiovascular risk, the benefit-to-risk ratio still clearly favors treatment.

Who Is at Higher Risk?

Research has identified several factors that may increase susceptibility to NAION while on semaglutide:

• Male sex — roughly 3x higher odds than women in the new study
• Older age — NAION is more common in adults over 50 regardless of medication use
• Pre-existing eye conditions — history of glaucoma, optic nerve issues, or diabetic retinopathy
• Small optic disc ("disc at risk") — an anatomical feature that predisposes to NAION
• Sleep apnea — a known independent risk factor for NAION
• Rapid weight loss — the proposed mechanism linking higher semaglutide doses to increased risk
• Prolonged diabetes duration and elevated HbA1c — vascular health may already be compromised
• Hypertension and cardiovascular disease — conditions affecting blood flow to the optic nerve

Understanding these risk factors can help patients and doctors make more informed decisions. For a broader look at potential side effects across GLP-1 medications, see our complete GLP-1 side effects guide.

What Ophthalmologists Are Saying

Expert reactions to the accumulating evidence have been measured — concerned but not panicked.

"Not a Reason to Stop"

Dr. Joseph Rizzo, the Mass General Brigham researcher whose 2024 study was the first to identify the signal, has been clear: "To be perfectly clear, I would not take my findings and use them to recommend that patients stop taking their medications." He emphasized that the cardiovascular and metabolic benefits of semaglutide are significant and well-documented.

"Premature to Conclude Causation"

Dr. Andrew Lee, a neuro-ophthalmologist, has cautioned that "it is premature to conclude that the association is a causal association. More research is necessary to test the hypothesis." He recommended that patients "make a careful, informed choice based on their individual risk profile."

"Temporary Vision Changes Are Different"

Dr. Raj Maturi, a retina specialist, has drawn an important distinction between NAION and the more common blurred vision that some patients experience when starting semaglutide. Blurred vision is typically temporary, "usually subsiding after three or four months" as the lens adjusts to changes in blood sugar levels. This is fundamentally different from NAION, which causes permanent vision loss.

Dr. Maturi advised: "Make sure to let your ophthalmologist know of any medications you are using, and get your eyes checked regularly."

Consensus Recommendations

The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society have issued joint guidance recommending:

1. Baseline eye exam: Patients starting a GLP-1 receptor agonist — especially those with diabetes, age-related macular degeneration, or other eye conditions — should have a comprehensive, dilated eye examination within 12 months prior to starting therapy or within one month of initiation.
2. Inform your eye doctor: Tell your ophthalmologist about all medications, including GLP-1 drugs.
3. Report symptoms immediately: Sudden, painless vision loss in one eye requires emergency evaluation — do not wait for a scheduled appointment.
4. Shared decision-making: Patients with pre-existing visual loss from any cause should discuss risks and benefits with both their prescribing doctor and ophthalmologist before starting semaglutide.

What About Other GLP-1 Medications?

One of the more reassuring findings in the new study is that not all GLP-1-related medications showed the same risk profile.

Mounjaro (tirzepatide): The study found no increased risk of NAION associated with tirzepatide, which works on both GLP-1 and GIP receptors. This does not definitively prove tirzepatide is safer for the eyes — it may simply have been studied less in this context — but the absence of a signal is notable. Our semaglutide vs. tirzepatide guide covers how these drugs differ in mechanism and outcomes.

Rybelsus (oral semaglutide): The oral tablet form showed no detectable NAION risk, likely because oral absorption produces lower and slower drug exposure than injections.

Wegovy Pill (oral semaglutide for weight loss): Novo Nordisk has been developing an oral version of semaglutide for weight management. If the injectable formulation's risk is related to peak drug levels and speed of absorption, an oral formulation could theoretically carry lower eye-related risk. Learn more about the Wegovy pill vs. injection comparison and what it could mean for patients.

What Should You Do If You Are Taking Wegovy?

If you are currently taking Wegovy or considering starting it, here is a practical action plan based on the current evidence:

Do NOT Stop Your Medication Without Talking to Your Doctor

This is the single most important point. The absolute risk of NAION remains very low, and stopping a medication that is providing significant cardiovascular, metabolic, and weight-management benefits could be far more harmful than the small eye risk. Always discuss medication changes with your prescribing physician.

Get a Baseline Eye Exam

If you have not had a comprehensive, dilated eye exam recently, schedule one. This is especially important if you:

• Are over 50
• Have diabetes or pre-diabetes
• Have any history of eye problems
• Have sleep apnea
• Have hypertension or cardiovascular disease

Know the Warning Signs of NAION

NAION typically presents as:

• Sudden vision loss (develops over hours to days, not weeks)
• Painless (unlike many other eye emergencies)
• One eye affected (not both simultaneously)
• Visual field loss — often the lower or upper half of vision in one eye disappears

If you experience any of these symptoms, seek emergency medical attention immediately. Early evaluation cannot reverse NAION, but it can rule out other treatable causes of vision loss.

Discuss Your Personal Risk Profile

Talk to your doctor about whether your individual risk factors (age, sex, eye anatomy, sleep apnea status, rate of weight loss) warrant any modifications to your treatment plan — such as slower dose escalation or additional monitoring.

Consider the Formulation

The evidence suggests injectable semaglutide carries more risk than oral semaglutide. If you are particularly concerned about eye health and an oral option is appropriate for your situation, this is worth discussing with your provider.

For those just starting to explore GLP-1 medications, our GLP-1 beginner's guide covers the fundamentals of how these drugs work, what to expect, and how to get started safely.

The Bigger Picture: GLP-1 Safety Monitoring

The semaglutide-NAION story illustrates a broader challenge in modern medicine: how do you monitor the long-term safety of a drug that has been adopted faster than almost any medication in history?

Semaglutide was originally approved for type 2 diabetes (as Ozempic) in 2017 and for weight management (as Wegovy) in 2021. In less than a decade, tens of millions of prescriptions have been written worldwide. The clinical trials that led to approval were large and rigorous, but even the biggest trials — like the 17,604-patient SELECT trial — may not detect a side effect that occurs in 1 out of every 10,000 users.

This is precisely why post-market surveillance systems like the FDA's FAERS database exist. The March 2026 study used this real-world data to identify a signal that would have been nearly impossible to detect in a controlled clinical trial. The system is working as intended — but it depends on both patients reporting symptoms and manufacturers properly documenting adverse events, which is why the FDA's recent warning letter to Novo Nordisk is significant.

The scientific community is responding appropriately: the WHO has flagged the risk, the EMA has updated product labels, the AAO has issued clinical guidance, and multiple research teams around the world are conducting larger, more rigorous studies to determine whether the association is truly causal and to quantify the precise risk.

What Comes Next

Several important developments are expected in the coming months:

• Novo Nordisk's response to the FDA warning letter, due within 15 business days
• Additional pharmacovigilance studies mandated by the WHO and EMA
• Prospective clinical studies designed to establish causation rather than just correlation
• Potential FDA label updates for semaglutide products sold in the United States
• Ongoing monitoring of tirzepatide (Mounjaro/Zepbound) for similar signals

Frequently Asked Questions

Can Wegovy cause blindness?

Wegovy has been associated with a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION), which causes sudden, painless vision loss — typically in one eye. A March 2026 study found Wegovy users had about 5 times the odds of developing NAION compared to Ozempic users. However, the absolute risk remains very low, affecting approximately 1 in 10,000 semaglutide users. NAION causes partial vision loss in the affected eye rather than complete blindness in both eyes, though the damage is generally permanent.

Is Ozempic safer for your eyes than Wegovy?

Based on current evidence, Ozempic appears to carry a lower risk of NAION than Wegovy. The March 2026 study found the odds of developing ischemic optic neuropathy were about 5 times higher with Wegovy than with Ozempic. Researchers believe this is dose-dependent — Wegovy is prescribed at up to 2.4 mg weekly compared to Ozempic's maximum of 2.0 mg. The oral tablet form, Rybelsus, showed no detectable increased risk. However, both medications contain semaglutide, and earlier studies found elevated NAION risk with semaglutide use in general.

Should I stop taking Wegovy because of the blindness risk?

No — do not stop taking Wegovy without consulting your doctor. Leading researchers, including Dr. Joseph Rizzo of Mass General Brigham who conducted one of the earliest studies on this topic, have explicitly stated they would not recommend patients stop their medications based on current findings. The absolute risk of NAION is very low, and the cardiovascular and metabolic benefits of semaglutide are well established. If you are concerned, discuss your individual risk profile with your prescribing physician and consider getting a baseline eye exam.

What are the warning signs of NAION (eye stroke)?

NAION typically presents as sudden, painless vision loss in one eye. You may notice that the upper or lower half of your visual field in one eye suddenly disappears or becomes very dim. The onset is usually over hours to days. Unlike many other eye conditions, there is typically no pain, redness, or warning. If you experience sudden vision changes in one eye — especially if you are taking semaglutide — seek emergency medical evaluation immediately. While NAION itself cannot currently be reversed, prompt evaluation can rule out other treatable causes of sudden vision loss.

Does Mounjaro (tirzepatide) carry the same eye risk as Wegovy?

The March 2026 study found no increased risk of NAION associated with Mounjaro (tirzepatide). This is a notable finding, though researchers caution that it does not definitively prove tirzepatide is safer — it may simply reflect less available data or different usage patterns. Tirzepatide works on both GLP-1 and GIP receptors and has a different molecular structure than semaglutide. If eye health is a significant concern for you, this difference may be worth discussing with your doctor when considering treatment options.

---

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. The information presented here should not be used to diagnose, treat, cure, or prevent any medical condition. Always consult with a qualified healthcare provider before making any decisions about medications, including starting, stopping, or changing doses of GLP-1 receptor agonists. Individual risk profiles vary, and your doctor can help you weigh the benefits and risks based on your personal health history.

-- The GLP-1 Daily Team